Cargando…
Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma
SIMPLE SUMMARY: Genetic testing promises to provide guidance for early diagnosis and treatment of cholangiocarcinoma (CCA). Due to the different mutation landscapes across populations and the paucity of sequencing data of Chinese patients with CCA, the existing mutation landscape is insufficient to...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600135/ https://www.ncbi.nlm.nih.gov/pubmed/36291846 http://dx.doi.org/10.3390/cancers14205062 |
_version_ | 1784816766075011072 |
---|---|
author | Ma, Kai Wang, Youpeng Zhang, Yuanzheng Sun, Hongfa Zhang, Xuhui Sun, Chuandong Zhang, Bingyuan Zhang, Ying Cheng, Haoyue Liu, Ao Wang, Mengyao Han, Bing |
author_facet | Ma, Kai Wang, Youpeng Zhang, Yuanzheng Sun, Hongfa Zhang, Xuhui Sun, Chuandong Zhang, Bingyuan Zhang, Ying Cheng, Haoyue Liu, Ao Wang, Mengyao Han, Bing |
author_sort | Ma, Kai |
collection | PubMed |
description | SIMPLE SUMMARY: Genetic testing promises to provide guidance for early diagnosis and treatment of cholangiocarcinoma (CCA). Due to the different mutation landscapes across populations and the paucity of sequencing data of Chinese patients with CCA, the existing mutation landscape is insufficient to reflect the mutation characteristics of Chinese patients. We retrospectively analyzed 72 Chinese patients with CCA who had received genetic testing of targeted capture sequencing. A total of 2152 somatic mutations were detected in 56 (77.78%, 56/72) patients, of which, the frequently mutated driver genes were TP53, KMT2D, KMT2C, BCOR, APC, BAP1, ARID1A, NF1, PIK3CA, KRAS, and LRP1B. Most mutations were enriched in NRF2, TP53, and TGF-Beta oncogenic signaling pathways and cadherin repeat domain which were associated with intercellular adhesion. We identified 118 novel pathogenic or likely pathogenic somatic mutations and 77 actionable alterations, which provided potential targets for early diagnosis and treatment planning of CCA. ABSTRACT: The early diagnosis and treatment of cholangiocarcinoma (CCA) remain a challenge worldwide. Genetic testing promises to solve these problems. Due to the different mutation landscapes across populations and the paucity of sequencing data of Chinese patients with CCA, the existing mutation landscape is insufficient to reflect the mutation characteristics of Chinese patients. Thus, we retrospectively analyzed 72 Chinese patients with CCA who had received genetic testing of targeted capture sequencing. A total of 2152 somatic mutations were detected in 56 (77.78%) patients, of which, the frequently mutated driver genes were TP53 (27.78%), KMT2D (23.81%), KMT2C (20.63%), BCOR (18.06%), APC (15.28%), BAP1 (13.89%), ARID1A (12.50%), NF1 (12.50%), PIK3CA (12.50%), KRAS (11.11%), and LRP1B (11.11%). Most mutations were enriched in NRF2, TP53, and TGF-Beta oncogenic signaling pathways and cadherin repeat domains which were associated with intercellular adhesion. Based on cancer-related public databases and multiple protein function prediction algorithms, we identified 118 novel pathogenic or likely pathogenic somatic mutations and 77 actionable alterations. Molecular analysis of tumors from a precision oncology perspective can provide potential targets for early diagnosis and treatment of CCA and assist physicians in clinical decision making. |
format | Online Article Text |
id | pubmed-9600135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96001352022-10-27 Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma Ma, Kai Wang, Youpeng Zhang, Yuanzheng Sun, Hongfa Zhang, Xuhui Sun, Chuandong Zhang, Bingyuan Zhang, Ying Cheng, Haoyue Liu, Ao Wang, Mengyao Han, Bing Cancers (Basel) Article SIMPLE SUMMARY: Genetic testing promises to provide guidance for early diagnosis and treatment of cholangiocarcinoma (CCA). Due to the different mutation landscapes across populations and the paucity of sequencing data of Chinese patients with CCA, the existing mutation landscape is insufficient to reflect the mutation characteristics of Chinese patients. We retrospectively analyzed 72 Chinese patients with CCA who had received genetic testing of targeted capture sequencing. A total of 2152 somatic mutations were detected in 56 (77.78%, 56/72) patients, of which, the frequently mutated driver genes were TP53, KMT2D, KMT2C, BCOR, APC, BAP1, ARID1A, NF1, PIK3CA, KRAS, and LRP1B. Most mutations were enriched in NRF2, TP53, and TGF-Beta oncogenic signaling pathways and cadherin repeat domain which were associated with intercellular adhesion. We identified 118 novel pathogenic or likely pathogenic somatic mutations and 77 actionable alterations, which provided potential targets for early diagnosis and treatment planning of CCA. ABSTRACT: The early diagnosis and treatment of cholangiocarcinoma (CCA) remain a challenge worldwide. Genetic testing promises to solve these problems. Due to the different mutation landscapes across populations and the paucity of sequencing data of Chinese patients with CCA, the existing mutation landscape is insufficient to reflect the mutation characteristics of Chinese patients. Thus, we retrospectively analyzed 72 Chinese patients with CCA who had received genetic testing of targeted capture sequencing. A total of 2152 somatic mutations were detected in 56 (77.78%) patients, of which, the frequently mutated driver genes were TP53 (27.78%), KMT2D (23.81%), KMT2C (20.63%), BCOR (18.06%), APC (15.28%), BAP1 (13.89%), ARID1A (12.50%), NF1 (12.50%), PIK3CA (12.50%), KRAS (11.11%), and LRP1B (11.11%). Most mutations were enriched in NRF2, TP53, and TGF-Beta oncogenic signaling pathways and cadherin repeat domains which were associated with intercellular adhesion. Based on cancer-related public databases and multiple protein function prediction algorithms, we identified 118 novel pathogenic or likely pathogenic somatic mutations and 77 actionable alterations. Molecular analysis of tumors from a precision oncology perspective can provide potential targets for early diagnosis and treatment of CCA and assist physicians in clinical decision making. MDPI 2022-10-16 /pmc/articles/PMC9600135/ /pubmed/36291846 http://dx.doi.org/10.3390/cancers14205062 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ma, Kai Wang, Youpeng Zhang, Yuanzheng Sun, Hongfa Zhang, Xuhui Sun, Chuandong Zhang, Bingyuan Zhang, Ying Cheng, Haoyue Liu, Ao Wang, Mengyao Han, Bing Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma |
title | Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma |
title_full | Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma |
title_fullStr | Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma |
title_full_unstemmed | Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma |
title_short | Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma |
title_sort | clinical practice of targeted capture sequencing to identify actionable alterations in cholangiocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600135/ https://www.ncbi.nlm.nih.gov/pubmed/36291846 http://dx.doi.org/10.3390/cancers14205062 |
work_keys_str_mv | AT makai clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT wangyoupeng clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT zhangyuanzheng clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT sunhongfa clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT zhangxuhui clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT sunchuandong clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT zhangbingyuan clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT zhangying clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT chenghaoyue clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT liuao clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT wangmengyao clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma AT hanbing clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma |